Loading...
XNAS
CMND
Market cap4mUSD
Jun 06, Last price  
0.95USD
1D
0.95%
1Q
-10.49%
IPO
-99.46%
Name

Clearmind Medicine Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
221.94%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-56.05%
-6,671-194,535-105,283-233,220-4,122,652-9,410,806-11,955,031-5,254,678
CFO
-5m
-9,124-105,588-63,006-264,452-2,835,029-5,083,5610-4,858,659

Profile

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
IPO date
May 15, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑10
Income
Revenues
Cost of revenue
4,666
8,798
8,533
Unusual Expense (Income)
NOPBT
(4,666)
(8,798)
(8,533)
NOPBT Margin
Operating Taxes
378
24
41
Tax Rate
NOPAT
(5,044)
(8,822)
(8,573)
Net income
(5,255)
-56.05%
(11,955)
27.04%
(9,411)
128.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,192
8,037
795
BB yield
Debt
Debt current
37
52
Long-term debt
70
52
Deferred revenue
Other long-term liabilities
1,959
Net debt
(6,757)
(4,005)
(355)
Cash flow
Cash from operating activities
(4,859)
(5,084)
CAPEX
(8)
Cash from investing activities
(238)
(8)
Cash from financing activities
6,254
8,434
698
FCF
(5,096)
(10,747)
(6,627)
Balance
Cash
6,863
4,005
440
Long term investments
284
20
Excess cash
6,863
4,005
460
Stockholders' equity
124
(1,189)
(4,052)
Invested Capital
3,036
1,903
2,595
ROIC
ROCE
585.56%
EV
Common stock shares outstanding
4,265
202
43
Price
Market cap
EV
EBITDA
(4,615)
(8,756)
(8,419)
EV/EBITDA
Interest
36
20
Interest/NOPBT